跳至主要内容
临床试验/NCT03839420
NCT03839420已完成不适用

Prospective Randomized Clinical Trial Comparing Early Rotation of Two Extended Depth of Focus Intraocular Lenses

Carl Zeiss Meditec AG1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2019年7月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
250
试验地点
1
主要终点
IOL axis

研究概览

简要总结

To demonstrate that the Carl Zeiss Meditec (CZM) Extended depth of focus (EDOF) Intraocular lens (IOL) is superior to the competitor EDOF IOL with respect to Rotational Stability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient informed of the consequences and constraints of the Clinical Investigational Plan and who has given his/her written informed consent
  • Patients of any gender, aged 18 or older
  • Assured follow-up examinations
  • Healthy eyes with clinically significant age related cataract requiring surgical treatment
  • Corrected distance visual acuity projected to be better than 0.2 logMAR after the cataract surgery, as determined by Investigator's medical judgment
  • Uni- and/or bilaterally regular corneal astigmatism ≥ 1.0 D and ≤ 3.0 D (confirmed by topography measurement)
  • Cataract density compatible with biometry measurement

排除标准

  • Patients unable to meet the limitations of the Clinical Investigational Plan or likely of non-cooperation during the trial
  • Patients whose freedom is impaired by administrative or legal order
  • Current participation in another drug or device investigation that affects patients vision
  • Ocular disorders, other than cataract, that could potentially cause future acuity loss
  • Have atonic pupil or physiologically small pupil (unable to dilate to at least 5 mm)
  • Any anterior segment pathology that could significantly affect outcomes (e.g. chronic or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.)
  • Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically significant corneal membrane dystrophies)
  • Any condition in the study eye that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, Floppy iris syndrome etc.)
  • History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus, epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or limit final postoperative visual prognosis
  • Pseudoexfoliation syndrome (according to investigator decision)
  • Pathologic miosis or Pharmacotherapy with miotic agent
  • Irregular astigmatism / Keratoconus
  • Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment.
  • All kind of infections (acute ocular disease, external / internal infection, systemic infection)
  • Traumatic cataract
  • Monophthalmic patient
  • Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus
  • Patient expected to require retinal laser treatment before the end of the last follow-up examination
  • Patient expected to require refractive laser treatment / refractive laser touch-up before the end of the last follow-up examination
  • Previous intraocular and corneal / refractive surgery
  • Current Systemic or ocular pharmacotherapy that effects patients vision (according to investigator decision)
  • Previous use of cytotoxic drugs or total body irradiation within last 2 years
  • Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient
  • Pregnancy and / or lactation period

结局指标

主要结局

IOL axis

时间窗: Immediately after the surgery

IOL axis will be analyzed based on images.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验